AUS
NZ
UK
CA
USA
IND
Highlights
- Novo Nordisk seeks FDA restrictions on compounded Ozempic.
- Company cites safety issues with unregulated, cheaper alternatives.
- FDA’s decision could impact patient access to compounded semaglutide.
Novo Nordisk (NYSE:NVO), a leading pharmaceutical company, is calling on the U.S. Food and Drug Administration (FDA) to take regulatory action against compounded versions of its popular weight-loss drug, Ozempic. The company’s request comes amid growing concerns over patient safety linked to unregulated, lower-cost copies of Ozempic, which are not FDA-approved. Novo Nordisk aims to prevent the production of these compounded alternatives by adding semaglutide, the active ingredient in Ozempic and Wegovy, to the FDA’s Demonstrable Difficulties for Compounding (DDC) list, which restricts compounding pharmacies from creating or distributing specific medications.
The move is a response to the rise in demand for Ozempic alternatives, which has spurred compounding pharmacies to offer non-branded versions of semaglutide at significantly lower prices. Some alternatives cost as little as $100 per month, appealing to patients who may face high costs or shortages in the availability of branded Ozempic. However, Novo Nordisk highlights that these compounded options pose significant safety risks due to potential inconsistencies in dosing and a lack of FDA oversight, which can lead to adverse effects.
Compounded drugs differ from generic medications in that they bypass FDA approval processes, raising concerns about their quality and safety. Novo Nordisk argues that the complex composition of semaglutide makes it challenging to produce safely outside of regulated pharmaceutical environments. Reports of hospitalizations and other severe adverse effects tied to compounded semaglutide versions have added weight to Novo’s concerns, according to FDA documentation. Novo Nordisk has also pursued legal action, filing lawsuits against various providers, including telehealth clinics and medspas, which offer these compounded versions of semaglutide.
This request from Novo Nordisk follows a similar effort by pharmaceutical company Eli Lilly, which faced supply shortages of its own GLP-1 drug, tirzepatide. Eli Lilly’s request to restrict compounded versions of tirzepatide was initially approved by the FDA, although the agency later reversed the listing. The ongoing debate reflects broader industry tensions around compounded medications and their place in the market, particularly for drugs experiencing high demand and limited supply.
The FDA’s review of Novo’s request has implications not only for Novo Nordisk but also for patients seeking affordable alternatives and for the compounding pharmacies and telehealth providers currently producing these options. The decision could reshape access to GLP-1 drugs in the U.S. and set a precedent for future actions concerning compounded medications.
